Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, announced a corporate presentation at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST. The company focuses on developing treatments targeting autoimmune diseases, organ transplant requirements, and ALS. Its lead compound, AT-1501, is an anti-CD40L antibody designed to enhance efficacy and safety by inhibiting CD40L, thus regulating immune responses. A replay of the presentation will be available for 30 days post-event on the company’s website.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a biopharmaceutical firm focused on autoimmune diseases and organ transplant treatments, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30pm EST. Interested participants can register here.
A replay will be available for 30 days on the company’s website. Eledon is developing AT-1501, an anti-CD40L antibody, for autoimmune diseases and transplants, aiming for improved safety and efficacy.
Eledon Pharmaceuticals reported its Q1 2021 financial results, highlighting continued enrollment in the Phase 2 trial of AT-1501 for ALS, with top line data expected in H1 2022. The company appointed four key executives, enhancing its leadership team. Q1 net loss was $8.5 million, or $0.57 per share, up from $8.2 million, or $8.52 per share, year-over-year. R&D expenses surged to $5.6 million, compared to $1.6 million in 2020. Eledon has $108.6 million in cash, ensuring operational funding into 2023. Upcoming milestones include initiating additional trials and presenting data at the American Society of Transplantation conference.
Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company, announced presentations for its lead product candidate, AT-1501, at the American Transplant Congress (ATC) from June 4-9, 2021. The presentations include Phase 1 data on AT-1501's safety, tolerability, and pharmacokinetics, alongside pre-clinical data demonstrating its effectiveness in preventing islet allograft rejection in nonhuman primates. Two additional posters will cover pharmacokinetics, toxicity, and characterization of AT-1501. More information is available on the ATC website.
Eledon Pharmaceuticals (NASDAQ: ELDN) plans to announce its financial results for Q1 2021 on May 13, 2021, after trading closes. The management will conduct a conference call and webcast at 4:30 PM ET to discuss these results. The company focuses on developing therapies for autoimmune diseases and ALS, with its lead compound AT-1501 targeting the CD40L pathway. This innovative approach aims to improve safety and efficacy in treatments. A recording of the event will be available on Eledon's website for one year.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced a new development strategy for AT-1501 in renal transplantation as requested by the FDA. The agency has asked for specific non-human primate data before starting a Phase 2 trial in the U.S. Consequently, Eledon will conduct evaluations in primate models, expected to be completed by late 2022. Despite this shift, other development programs continue as planned, and no safety concerns regarding AT-1501 have been reported. The CEO emphasized the potential of AT-1501 as a treatment option for renal transplant patients.
Eledon Pharmaceuticals has announced the appointments of David Hovland, Ph.D. as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer. Dr. Hovland brings over 20 years of R&D experience, previously serving at Urovant Sciences and Allergan, while Mr. Smith has a successful track record at Urovant and Allergan. Their expertise is expected to advance the development of AT-1501, a novel antibody targeting the CD40 ligand. The company will issue stock options as inducement grants for their roles.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2020 results, highlighting a net loss of $5.9 million for Q4 and $22.8 million for the year. The company has $114.2 million in cash as of December 31, 2020, allowing it to fund multiple Phase 2 trials of its lead asset, AT-1501. Key milestones include ongoing ALS trials and islet cell transplantation trials expected to start in Q2 2021. The acquisition of Anelixis Therapeutics in September 2020 has reshaped Eledon's focus on autoimmune diseases and transplantation.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its financial results for Q4 and the full year 2020 on March 30, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET. The company, focused on developing treatments for autoimmune diseases and ALS, is advancing its lead compound, AT-1501, a targeted anti-CD40L antibody. Eledon aims to provide enhanced therapeutic solutions in immunology and transplantation.
Eledon Pharmaceuticals has appointed Jeff Bornstein, M.D. as Chief Medical Officer effective April 5, 2021, and Paul Little as Chief Financial Officer immediately. These appointments aim to strengthen the leadership team as Eledon advances its Phase 2 trial of AT-1501 for ALS and plans for additional trials. Dr. Bornstein has extensive experience in biopharmaceuticals, previously working with major companies like Takeda and Biogen, while Mr. Little brings over 30 years of finance and operations expertise from roles in Sientra and Allergan. Both executives will receive inducement grants of stock options.